Cardiac Sarcoidosis, Sarcoidosis
Conditions
Keywords
Cardiac Sarcoidosis, Sarcoidosis
Brief summary
There are no published clinical consensus guidelines on the treatment of cardiac sarcoidosis. Corticosteroid therapy is advocated by some experts, but is based on small observational studies, with varied clinical response. Objectives of this trial: * to systemically assess the response of patients with cardiac sarcoidosis, to treatment with corticosteroids * to identify the clinical predictors of response to treatment with corticosteroids * to assess the utility of imaging with PET and MRI to predict response to treatment with corticosteroids * to determine the prevalence of cardiac sarcoidosis in young patients with unexplained heart block and in patients with unexplained dilated cardiomyopathy associated with ventricular tachycardia * to use the data from this pilot study to assess the need, feasibility, and sample size for a larger multicentre trial
Interventions
DRUGPrednisone
Prednisone 0.5 mg/Kg orally per day for 3 months
Sponsors
Ottawa Heart Institute Research Corporation
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* evidence of clinical cardiac sarcoidosis causing significant conduction system disease (defined as complete right bundle branch block and left axis deviation or left bundle branch block or second or third degree AV block in young patients (\< 60 yrs) AND/OR * evidence of clinical cardiac sarcoidosis causing non-ischemic dilated cardiomyopathy and sustained ventricular tachycardia AND * PET or MRI imaging supporting the diagnosis of cardiac sarcoidosis
Exclusion criteria
* unable or unwilling to provide informed consent * history of noncompliance of medical therapy * patients with active infection * patients with active inflammatory disease not related to sarcoidosis * patients with other known causes of heart block or LV dysfunction * patients with known active malignancy * patients wwho are pregnant or lactating * patients with other indications for steroids
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Heart failure hospitalization and sustained ventricular arrhythmia | 3 months | Considered a responder to steroid therapy if alive, no heart failure hospitalization and no sustained ventricular arrhythmia, and improvement in one or both of: 1. LV function (defined as 5% increase in EF units or 10% decrease in volumes) 2. greater than or equal to one heart block grade (defined as improvement from eg. third to second degree AV block or resolution of bundle branch block) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in disease activity by PET imaging | 3 months | 1. Change in disease activity as assessed by PET imaging (comparing pre-treatment to 3 month scans) 2. Atrial fibrillation burden during the 3 month treatment period (from pacemaker or ICD diagnostics) 3. Ventricular arrhythmia burden during the 3 month treatment period 4. Percent of ventricular pacing (pacemaker programming will be standardized in all patients) 5. Patient Quality of life (using SF-36 questionnaire) |
Countries
Canada
Outcome results
None listed